To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.
Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.
The method of individualized treatment effect prediction of fenofibrate on major cardiovascular events risk reduction in T2D can be used to guide clinical decision-making.
Multiple clinical studies have examined the efficacy of pitavastatin.
Risk of both ischemic stroke and coronary heart disease was elevated with high triglycerides and low high-density lipoprotein cholesterol.
The new guidelines call for treating low-density lipoprotein cholesterol in specific patient groups to lower goals than previously recommended.
Too few American young adults are receiving needed statin medications, according to findings published in JAMA Cardiology.
Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia.
Women and minorities with HIV are less frequently tested for dyslipidemia, according to a new study from IDWeek 2016.
Even if the impact of a given medication on lipid profile is relatively minimal, and therefore unlikely to independently affect ASCVD risk, the cumulative effect is important and cannot be overlooked.
Blacks have increased incidence of hypertension, diabetes, and dyslipidemia but not atrial fibrillation.
Having both diseases raises a patient's chances for developing diabetes.
Serum 25-hydroxyvitamin D levels correlated with risk for dyslipidemia.
Adolescents with autism spectrum disorder appear to be more likely to develop the disease.
Follicle-stimulating hormone may interact with its receptors and lead to elevated LDL cholesterol in postmenopausal women.
Researchers noted an improvement in lipid profile for nutraceuticals alone or in combination in statin-intolerant patients.
Key features include elimination of treatment targets and additional testing only when rationale clear.
Findings in older men with high cholesterol and low testosterone.
Researchers have discovered that a common medication indicated for the treatment of high cholesterol may stimulate the same peroxisome proliferator-activated receptors (PPARs) as cannabinoids, which could lead to a new class of cannabis-like drugs to treat a range of conditions.
An increasingly sedentary lifestyle has been linked to coronary calcification, regardless of exercise or traditional risk factors.
Many patients with diabetes may not be adhering to medication regimens and are therefore experiencing higher rates of cardiac events.
About half of extremely obese children had elevated blood pressure or dyslipidemia.
Recommendations based on existing guidelines for general population; many gaps in knowledge.
About one in five had dyslipidemia; one in ten had high or borderline BP in 2011 to 2012.
Overweight or obese adults with risk cardiovascular disease risk factors should be referred for intensive behavioral counseling.
Endocrinology Advisor Articles
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Transgender Youth Not Willing to Delay Hormone Therapy for Fertility Preservation
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Plasma Methylglyoxal Levels Associated With CVD, Mortality in Type 2 Diabetes
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- AMA: Federal Government Must Tackle Rising Insulin Prices
- Diabetes Medication Reconciliation May Reduce Risk of ED Visits